Abstract:Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the "caffeine-like effects" of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki < 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg–1, i.p. rats). Compound 12 (2 mg kg–1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00914?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914</a>.Spectroscopic and analytical data; general LC–MS analytics; general synthesis, fluorescence characterization of compound 12 (ST-1992); drug-likeness of synthetized MTLs 4 (ST-2001) and 12 (ST-1992); cell viability of human neuroblastoma cells treated with MTLs 2, 4 (ST-2001) , and 6; in vitro radioligand binding experiments for compounds 4 (ST-2001) and 12 (ST-1992); in vivo studies of compound 4 (ST-2001); additional in vivo evaluation of compound 12 (ST-1992); and experimental part with references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">CSV</a>)Modeling structure of A2AR with preladenant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">PDB</a>)Modeling structure of A2AR with ST-1992 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">PDB</a>)This article has not yet been cited by other publications.

Design and Synthesis of Five‐membered Heterocyclic Derivatives of Istradefylline with Comparable Pharmacological Activity

Design, Synthesis, and Biological Activity Studies of Istradefylline Derivatives Based on Adenine As A2A Receptor Antagonists.

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Discovery of Indolylpiperazinylpyrimidines with Dual-Target Profiles at Adenosine A2A and Dopamine D2 Receptors for Parkinson's Disease Treatment.

Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines As A(2a) Adenosine Receptor Antagonists for the Treatment of Parkinson'S Disease

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Design, Synthesis And Inhibitory Activities Of 8-(Substituted Styrol-Formamido)Phenyl-Xanthine Derivatives On Monoamine Oxidase B

Adenosine A 2A R/A 1 R Antagonists Enabling Additional H 3 R Antagonism for the Treatment of Parkinson’s Disease

Efficacy and safety of istradefylline for Parkinson’s disease: A systematic review and meta-analysis

Synthesis of 5-amido-1H-imidazo[5,4-b]pyridine derivatives and their angiotensin II receptor antagonistic activities

Synthesis and Biological Investigation of Tetrahydropyridopyrimidinone Derivatives As Potential Multireceptor Atypical Antipsychotics.

Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors

Exploring the Structural Determinants of Novel Xanthine Derivatives As A2B Adenosine Receptor Antagonists: a Computational Study

Discovery of Novel Benzimidazole Derivatives as Selective and Reversible Monoamine Oxidase B Inhibitors for Parkinson's Disease Treatment

Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer’s Disease